<DOC>
	<DOC>NCT02546375</DOC>
	<brief_summary>The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting</brief_summary>
	<brief_title>A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<criteria>Diagnosis of Ph+ CML aged â‰¥18 years at bosutinib initiation. Prescribed bosutinib (irrespective of the phase of their disease) EITHER in normal clinical practice since it received marketing authorisation (27th March 2013) by the EMA11 OR via the compassionate use programme prior to marketing authorization. Where required, evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Prescribed bosutinib as part of an interventional clinical trial programme. Initiated on bosutinib less than 3 months prior to data collection taking place.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>chronic myeloid leukaemia</keyword>
	<keyword>retrospective</keyword>
	<keyword>observational</keyword>
</DOC>